⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15772465 | 0.97 | — | — | |
| SCHEMBL27323 | 0.93 | — | — | |
| SCHEMBL1831166 | 0.93 | — | — | |
| SCHEMBL1286818 | 0.90 | — | — | |
| SCHEMBL1117505 | 0.90 | CHEK1 (0.32) | — | |
| SCHEMBL162968 | 0.90 | CHEK1 (0.32) | — | |
| SCHEMBL16877581 | 0.90 | CHEK1 (0.32) | — | |
| Hydrochloric Acid SCHEMBL5280351 | 0.87 | CHEK1 (0.31) | — | |
| SCHEMBL17797679 | 0.87 | CHEK1 (0.34) | — | |
| Hydrochloric Acid SCHEMBL15008003 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107062-A1 | STAT6 DEGRADERS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4688792-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4688784-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | claimed |
| US-12404283-B2 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-09-02 | — | — | US | claimed |
| EP-4547672-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250129100-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-04-24 | — | — | US | claimed |
| CN-119233976-A | Modulators of c-MYC mRNA translation and their use in the treatment of cancer | 艾尼莫生物科技公司 | 2024-12-31 | — | — | CN | claimed |
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | claimed |
| US-20240343736-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-10-17 | — | — | US | claimed |
| WO-2024213032-A1 | INDOLE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 纽欧申医药(上海)有限公司 | 2024-10-17 | — | — | WO | claimed |
| WO-2024206766-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2024-10-03 | — | — | WO | claimed |
| WO-2024206747-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2024-10-03 | — | — | WO | claimed |
| WO-2024010762-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2024-01-11 | — | — | WO | claimed |
| CN-122071475-A | Ternary condensed ring derivative and medical application thereof | 杭州百新生物医药科技有限公司 | 2026-05-22 | — | — | CN | disclosed |
| WO-2026107062-A1 | STAT6 DEGRADERS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12630562-B2 | Piperidylurea compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
| WO-2012076674-A1 | IMIDAZO(4,5-B)PYRIDINE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | WO | disclosed |
| US-4353913-A | ANTHELMINTICS | BAYER AKTIENGESELLSCHAFT (DE) | 1982-10-12 | — | — | US | disclosed |
| US-4287199-A | USEFUL AS ANTHELMINITICS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-09-01 | — | — | US | disclosed |